Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

• Status: Completed
• Trial end date: 2017-09-03
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Trevi Therapeutics
• Treatments: Nalbuphine

Criteria

Inclusion Criteria:

• Subject completed participation in the TR03 study

Exclusion Criteria:

• Medical condition or other factors that in the opinion of the Investigator may interfere with the conduct of the study.

• Subject is a pregnant or lactating female